# Safety and Pharmacokinetic Characteristics of DKF-313

> **NCT02352311** · PHASE1 · COMPLETED · sponsor: **Dongkook Pharmaceutical Co., Ltd.** · enrollment: 54 (actual)

## Conditions studied

- Benign Prostate Hyperplasia
- Healthy

## Interventions

- **DRUG:** DKF-313
- **DRUG:** AVODART
- **DRUG:** CIALIS

## Key facts

- **NCT ID:** NCT02352311
- **Lead sponsor:** Dongkook Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02352311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02352311, "Safety and Pharmacokinetic Characteristics of DKF-313". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02352311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*